This powerful workflow, created over 20 years by the company’s renowned pioneers in phosphoproteomics, is uniquely able to develop next-generation multi-drug diagnostics.
Kinomica has 48 granted patents across 6 patent families in major territories, securing strategically significant IP rights in the phosphoproteomic (and broader post-translational modifications) space.